Recurring neurocardiogenic syncope after vaccination

 A 21-year-old Caucasian woman with a medical history of hypothyroidism secondary to Hashimoto’s thyroiditis, chronic migraine headaches without aura, and anxiety disorder presented to the outpatient electrophysiology clinic following three episodes of syncope within three months - one day, 4 week and 8 weeks after the first dose of the Pfizer BioNTech SARS-CoV-2 vaccine. She was placed on a two-week Holter monitor to rule out conduction abnormalities. An echocardiogram revealed normal left ventricular function, normal wall motion, and no evidence of pericardial effusion, but four days later she was found to have been in a normal sinus rhythm that progressed to sinus bradycardia followed by a sinus arrest with no underlying escape for 8.4 seconds that correlated with her syncope. She then had a few beats of sinus bradycardia, followed by another 3.1-second pause of the same mechanism. Since Holter monitoring during successive episodes showed progressive bradycardia followed by a prolonged sinus arrest, a diagnosis of cardioinhibitory neurocardiogenic syncope was established. 

A few days later she presented with severe, sharp, left-sided chest pain that was positional in nature, worsening on lying down, and improving on leaning forward. She was treated for a right ventricular apical lead perforation and pericardial effusion. The patient eventually required pacemaker placement that resulted in the total resolution of her symptoms. Recurrent neurocardiogenic syncope is a possible adverse event following the novel mRNA Pfizer-BioNTech COVID-19 vaccine.

Other cases described in medical literature include  a 70-year-old man with syncopedue to a long QT interval, 3 days after his first COVID-19 AstraZeneca Vaccination and a young man with fever-induced syncope diagnosed with Brugada Syndrome after the second dose of the Moderna COVID-19 vaccine. 

Brugada syndrome is linked to mutations in 16 ion channel genes. Hashimoto thyroiditis is thought to result from a combination of genetic and environmental factors.

REFERENCES

Ghoweba M, Sabayon MD. Syncope With Sinus Arrest Following a Single Dose of a COVID-19 Vaccine. Cureus. 2023 Jan 28;15(1):e34309. doi: 10.7759/cureus.34309. PMID: 36860236; PMCID: PMC9970110.

Azdaki N, Farzad M. Long QT interval and syncope after a single dose of COVID-19 vaccination: a case report. Pan African Medical Journal. 2021 Sep 30;40(1).

Okuyama T, Kabutoya T, Gonda Y, Kashihara KK, Imai Y, Morisawa Y, Kario K. Syncope after COVID-19 Vaccination in a Young Man with Unmasking Brugada Syndrome. Internal Medicine. 2023:1250-22.

Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more